Research programme: bradykinin B1 receptor antagonists - Jerini
Latest Information Update: 24 Mar 2010
At a glance
- Originator Jerini
- Class Small molecules
- Mechanism of Action Bradykinin B1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Inflammation; Pain
Most Recent Events
- 05 Dec 2007 Early research in Pain in Germany (PO)
- 05 Dec 2007 Early research in Inflammation in Germany (PO)